Review ArticleClinical Review

Current Oral Antiplatelets: Focus Update on Prasugrel

Jinu John and Santhosh K. G. Koshy
The Journal of the American Board of Family Medicine May 2012, 25 (3) 343-349; DOI: https://doi.org/10.3122/jabfm.2012.03.100270

References

  1. 1.↵
    1. Lloyd-Jones D,
    2. Adams RJ,
    3. Brown TM,
    4. et al
    Writing Group Members, Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation. 2010;121:e46–e15.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Jang IK,
    2. Gold HK,
    3. Ziskind AA,
    4. et al
    . Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989;79(4):920–8.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Angiolillo DJ,
    2. Bhatt DL,
    3. Gurbel PA,
    4. Jennings LK
    . Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol. 2009;103(3 Suppl):40A–51A.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Chen ZM,
    2. Jiang LX,
    3. Chen YP,
    4. et al
    . Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005;366:1607–21.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Symeonidis A,
    2. Kouraklis-Symeonidis A,
    3. Seimeni U,
    4. et al
    . Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases. Am J Hematol. 2002;71:24–32.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Mehta SR,
    2. Yusuf S,
    3. Peters RJ,
    4. et al
    . Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–33.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Yusuf S,
    2. Zhao F,
    3. Mehta SR,
    4. Chrolavicius S,
    5. Tognoni G,
    6. Fox KK
    . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Angiolillo DJ,
    2. Fernandez-Ortiz A,
    3. Bernardo E,
    4. et al
    . Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49(14):1505–16.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    1. Farid NA,
    2. Smith RL,
    3. Gillespie TA,
    4. et al
    . The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007;35:1096–1104.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Niitsu Y,
    2. Jakubowski JA,
    3. Sugidachi A,
    4. et al
    . Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost. 2005;31:184–94.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Sugidachi A,
    2. Ogawa T,
    3. Kurihara A,
    4. et al
    . The greater in vivo antiplatelet effects of prasugrel compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to clopidogrel's active metabolite. J Thromb Haemost 2007;5:1545–1551.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Jernberg T,
    2. Payne CD,
    3. Winters KJ,
    4. et al
    . Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006;27(10):1166–73.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Weerakkody GJ,
    2. Jakubowski JA,
    3. Brandt JT,
    4. et al
    . Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol. 2007;100:331–6.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Brandt JT,
    2. Payne CD,
    3. Wiviott SD,
    4. et al
    . A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007;153:66.e9–16.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Jakubowski JA,
    2. Winters KJ,
    3. Naganuma H,
    4. Wallentin L
    . Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007;25(4):357–74.
    OpenUrlPubMedWeb of Science
  18. 18.↵
    1. Wiviott SD,
    2. Braunwald E,
    3. McCabe CH,
    4. et al
    . Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Wiviott SD,
    2. Braunwald E,
    3. Angiolillo DJ,
    4. et al
    . Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel–Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118(16):1626–36.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Wiviott SD,
    2. Brunwald E,
    3. McCabe CH,
    4. et al
    . Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomized trial. Lancet. 2008;371:1353–63.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Mahoney EM,
    2. Wang K,
    3. Arnold SV,
    4. et al
    . Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction TRITON-TIMI 38. Circulation. 2010;121:71–9.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Tran M,
    2. Tafreshi J,
    3. Pai RG
    . Combination of clopidogrel and proton pump inhibitors: implications for clinicians. J Cardiovasc Pharmacol Ther 2010;15:326–37.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Small DS,
    2. Farid NA,
    3. Payne CD,
    4. et al
    . Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008;48(4):475–84.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. O'Donoghue ML,
    2. Braunwald E,
    3. Antman EM,
    4. et al
    . Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials. Lancet. 2009;374(9694):989–97.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Bhatt DL
    . Prasugrel in clinical practice. N Engl J Med. 2009;361(10):940–2.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Colwell JA,
    2. Halushka PV,
    3. Sarji K,
    4. et al
    . Altered platelet function in diabetes mellitus. Diabetes. 1976;25(2 Suppl):826–31.
    OpenUrlPubMedWeb of Science
  27. 27.↵
    1. Geisler T,
    2. Anders N,
    3. Paterok M,
    4. et al
    . Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care. 2007;30(2):372–4.
    OpenUrlFREE Full Text
  28. 28.↵
    A comparison of prasugrel and clopidogrel in acute coronary syndrome subjects (TRILOGY ACS). ClinicalTrials.gov identifier: NCT00699998. 16 June 2008; updated 19 January 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT00699998?term=NCT00699998&rank=1. Accessed 15 March 2012.
  29. 29.↵
    1. Wallentin L,
    2. Becker RC,
    3. Budaj A,
    4. et al
    . Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–57.
    OpenUrlCrossRefPubMedWeb of Science
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section